Sinicrope FA, Ou FS, Arnold D, Peters WR, Behrens RJ, Lieu CH, Matin K, Cohen DJ, Potter SL, Nixon AB, Kottschade LA, Kathol E, Frankel WL, Shergill A, Hsu D, Reinacher-Schick A, Mehan P, Gold PJ, Khalil MF, Zemla T, Gatten C, O’Reilly EM, Meyerhardt JA. Atezolizumab plus FOLFOX for Stage III Mismatch Repair-Deficient Colon Cancer. N Engl J Med. 2026 Mar 26;394(12):1155-1166. doi: 10.1056/NEJMoa2507874. PMID: 41880612; PMCID: PMC13020640.
Publication Citation
Abstract
Standard adjuvant chemotherapy for stage III colon cancer consists of a fluoropyrimidine plus oxaliplatin regimen. The phase 3 ATOMIC trial evaluated whether the addition of atezolizumab (anti-PD-L1) to modified FOLFOX6 (mFOLFOX6) improves outcomes in patients with stage III colon cancer with deficient mismatch repair (dMMR) status. Patients with resected stage III dMMR tumors were randomized (1:1) to receive adjuvant atezolizumab plus mFOLFOX6 for 6 months with atezolizumab continued as monotherapy (total 12 months) versus mFOLFOX6 for 6 months. The primary endpoint was disease-free survival; secondary endpoints were overall survival and adverse event profile.